Orhan Efe is a Nephrology physician affiliated with Harvard University. OpenAlex indexes 48 publications with 438 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Boston, MA 021142696
Telephone
617-726-3706Provider last certified this registry record 16 May 2022.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20252 payments
- Apellis Pharmaceuticals, Inc.Program year20253 payments
- Travere Therapeutics, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
61.6%Angiotensin receptor blocker (ARB)22.3%Losartan Potassium80%Losartan-Hydrochlorothiazide20%Part D<11 patientsLoop diuretic9.7%Furosemide63%Torsemide37%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
25.8%Corticosteroid12.6%Prednisone100%Part D≥19 patientsH2 blocker5.2%Famotidine100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
4.2%Xanthine oxidase inhibitor4.2%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies
Clinical Kidney Journal
2026 - Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series
Kidney International Reports
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”